<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02111083</url>
  </required_header>
  <id_info>
    <org_study_id>15418</org_study_id>
    <secondary_id>F3Z-EW-IOQM</secondary_id>
    <nct_id>NCT02111083</nct_id>
  </id_info>
  <brief_title>A Study of 2 Different Formulations of Insulin Lispro in Healthy Participants</brief_title>
  <official_title>Evaluation of the Bioequivalence of Two Formulations of Insulin Lispro in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study involves 4 injections of insulin lispro and its purpose is to:

        -  Determine if 2 formulations of insulin lispro are treated by the body in a similar way.

        -  Compare how the 2 formulations of insulin lispro affect blood sugar level.

        -  Determine the safety of each insulin lispro formulations and any side effects that might
           be associated with them when given to healthy participants. The study is expected to
           last up to approximately 9 weeks for each participant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Area Under the Serum Insulin Concentration Versus Time Curve From Zero to Time of Return to Baseline (AUC0-tlast)</measure>
    <time_frame>Day 1, predose through 8 hours post dose in each period.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Maximum Serum Insulin Concentration (Cmax)</measure>
    <time_frame>Day 1, predose through 8 hours post dose in each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Area Under the Curve(AUC)</measure>
    <time_frame>Zero to infinity [AUC(0-âˆž)]</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: Time of Maximum Observed Serum Concentration (Tmax)</measure>
    <time_frame>Day 1, predose through 8 hours post dose in each period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Parameter: Total Amount of Glucose Infused (Gtot)</measure>
    <time_frame>Day1, predose through 8 hours post dose in each period.</time_frame>
    <description>The total amount of glucose infused during the euglycemic clamp procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Parameter: Maximum Glucose Infusion Rate (Rmax)</measure>
    <time_frame>Day 1, predose through 8 hours post dose in each period.</time_frame>
    <description>The maximum observed glucose infusion rate during the euglycemic clamp procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Parameter: Time of Maximum Glucose Infusion Rate (tRmax)</measure>
    <time_frame>Day 1, predose through 8 hours post dose in each period.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Insulin Lispro A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin Lispro A 20 units (U) of strength 200 units per milliliter (U/mL) (U-200)administered subcutaneously (SC) once in two of four study periods.(Two doses of test [T]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Lispro B 20 units (U) of strength 100 U/mL (U-100) administered SC once in two of four study periods.(Two doses of reference [R]).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>LY275585 administered SC.</description>
    <arm_group_label>Insulin Lispro A</arm_group_label>
    <arm_group_label>Insulin Lispro B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are healthy males or females

          -  Body mass index (BMI) between 18.5 and 29.9 kilogram per meter squared (kg/m^2)

          -  Are nonsmokers

          -  Have normal blood pressure and pulse rate, a normal electrocardiogram (ECG), and
             clinical laboratory test results within normal reference range at screening.

        Exclusion Criteria:

          -  History of first-degree relatives known to have diabetes mellitus

          -  Evidence of significant active neuropsychiatric disease

          -  Evidence of an acute infection with fever or infectious disease

          -  Intend to use over-the-counter or prescription medication (apart from vitamin/mineral
             supplements, occasional paracetamol, or birth control methods).

          -  Have used systemic glucocorticoids within 3 months prior to entry into the study.

          -  Have donated blood of 1 unit or more within the last 3 months prior to study entry

          -  Excessive alcohol intake

          -  Have a fasting venous blood glucose (fasting blood glucose [FBG], plasma) &gt;6
             millimoles per liter (mmol/L) at screening

          -  Have positive hepatitis B surface antigen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <zip>117597</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <results_first_submitted>May 4, 2015</results_first_submitted>
  <results_first_submitted_qc>May 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2015</results_first_posted>
  <last_update_submitted>May 4, 2015</last_update_submitted>
  <last_update_submitted_qc>May 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Insulin Lispro Dosing Sequence TRTR</title>
          <description>Each subject was administered insulin lispro A 20 units (U) of strength 200 units per milliliter (U/mL) (U-200) (test [T] on 2 occasions) and insulin lispro B 20 units (U) of strength 100 U/mL (U-100) (reference [R] on 2 occasions).Subjects were randomly assigned to dosing sequences TRTR.</description>
        </group>
        <group group_id="P2">
          <title>Insulin Lispro Dosing Sequence RTRT</title>
          <description>Each subject was administered insulin lispro A 20 units (U) of strength 200 units per milliliter (U/mL) (U-200) (test [T] on 2 occasions) and insulin lispro B 20 units (U) of strength 100 U/mL (U-100) (reference [R] on 2 occasions).Subjects were randomly assigned to dosing sequences RTRT.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Interval Between Dosing (7-8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Interval Between Dosing (7-8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Interval Between Dosing (7-8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Fourth Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Insulin Lispro Dosing Sequence TRTR</title>
          <description>Each subject was administered insulin lispro A U-200 (test [T] on 2 occasions) and insulin lispro B U-100(reference [R] on 2 occasions).Subjects were randomly assigned to dosing sequences TRTR.</description>
        </group>
        <group group_id="B2">
          <title>Insulin Lispro Dosing Sequence RTRT</title>
          <description>Each subject was administered insulin lispro A U-200 (test [T] on 2 occasions) and insulin lispro B U-100 (reference [R] on 2 occasions). Subjects were randomly assigned to dosing sequences RTRT.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.9" spread="6.1"/>
                    <measurement group_id="B2" value="30.4" spread="8.2"/>
                    <measurement group_id="B3" value="31.7" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameter: Area Under the Serum Insulin Concentration Versus Time Curve From Zero to Time of Return to Baseline (AUC0-tlast)</title>
        <time_frame>Day 1, predose through 8 hours post dose in each period.</time_frame>
        <population>All participants who had at least one study treatment and had evaluable pharmacokinetic (PK) data.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Lispro A</title>
            <description>Insulin Lispro A U-200 administered subcutaneously (SC) once in two of four study periods. (Two doses of test [T]).</description>
          </group>
          <group group_id="O2">
            <title>Insulin Lispro B</title>
            <description>Insulin Lispro B U-100 administered SC once in two of four study periods. (Two doses of reference [R]).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: Area Under the Serum Insulin Concentration Versus Time Curve From Zero to Time of Return to Baseline (AUC0-tlast)</title>
          <population>All participants who had at least one study treatment and had evaluable pharmacokinetic (PK) data.</population>
          <units>picomole*hour/liter (pmol*h/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2200" spread="16"/>
                    <measurement group_id="O2" value="2230" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric least square means</param_type>
            <param_value>0.986</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.965</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameter: Maximum Serum Insulin Concentration (Cmax)</title>
        <time_frame>Day 1, predose through 8 hours post dose in each period</time_frame>
        <population>All participants who had at least one study treatment and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Lispro A</title>
            <description>Insulin Lispro A U-200 administered subcutaneously (SC) once in two of four study periods. (Two doses of test [T]).</description>
          </group>
          <group group_id="O2">
            <title>Insulin Lispro B</title>
            <description>Insulin Lispro B U-100 administered SC once in two of four study periods. (Two doses of reference [R]).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: Maximum Serum Insulin Concentration (Cmax)</title>
          <population>All participants who had at least one study treatment and had evaluable PK data.</population>
          <units>picomole/liter (pmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="744" spread="38"/>
                    <measurement group_id="O2" value="851" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric least square means</param_type>
            <param_value>0.872</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.828</ci_lower_limit>
            <ci_upper_limit>0.919</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter: Time of Maximum Observed Serum Concentration (Tmax)</title>
        <time_frame>Day 1, predose through 8 hours post dose in each period.</time_frame>
        <population>All participants who had at least one study treatment and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Lispro A</title>
            <description>Insulin Lispro A U-200 administered subcutaneously (SC) once in two of four study periods. (Two doses of test [T]).</description>
          </group>
          <group group_id="O2">
            <title>Insulin Lispro B</title>
            <description>Insulin Lispro B U-100 administered SC once in two of four study periods. (Two doses of reference [R]).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: Time of Maximum Observed Serum Concentration (Tmax)</title>
          <population>All participants who had at least one study treatment and had evaluable PK data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.5" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1" lower_limit="0.5" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0.375</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Parameter: Total Amount of Glucose Infused (Gtot)</title>
        <description>The total amount of glucose infused during the euglycemic clamp procedure.</description>
        <time_frame>Day1, predose through 8 hours post dose in each period.</time_frame>
        <population>All participants who had at least one study treatment and had evaluable pharmacodynamic(PD) data.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Lispro A</title>
            <description>Insulin Lispro A U-200 administered subcutaneously (SC) once in two of four study periods. (Two doses of test [T]).</description>
          </group>
          <group group_id="O2">
            <title>Insulin Lispro B</title>
            <description>Insulin Lispro B U-100 administered SC once in two of four study periods. (Two doses of reference [R]).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Parameter: Total Amount of Glucose Infused (Gtot)</title>
          <description>The total amount of glucose infused during the euglycemic clamp procedure.</description>
          <population>All participants who had at least one study treatment and had evaluable pharmacodynamic(PD) data.</population>
          <units>grams (g)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" spread="31"/>
                    <measurement group_id="O2" value="120" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric least square means</param_type>
            <param_value>0.986</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.954</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Parameter: Maximum Glucose Infusion Rate (Rmax)</title>
        <description>The maximum observed glucose infusion rate during the euglycemic clamp procedure.</description>
        <time_frame>Day 1, predose through 8 hours post dose in each period.</time_frame>
        <population>All participants who had at least one study treatment and had evaluable PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Lispro A</title>
            <description>Insulin Lispro A U-200 administered subcutaneously (SC) once in two of four study periods. (Two doses of test [T]).</description>
          </group>
          <group group_id="O2">
            <title>Insulin Lispro B</title>
            <description>Insulin Lispro B U-100 administered SC once in two of four study periods. (Two doses of reference [R]).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Parameter: Maximum Glucose Infusion Rate (Rmax)</title>
          <description>The maximum observed glucose infusion rate during the euglycemic clamp procedure.</description>
          <population>All participants who had at least one study treatment and had evaluable PD data.</population>
          <units>milligrams per minute (mg/min)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503" spread="36"/>
                    <measurement group_id="O2" value="526" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric least square means</param_type>
            <param_value>0.950</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.901</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Parameter: Time of Maximum Glucose Infusion Rate (tRmax)</title>
        <time_frame>Day 1, predose through 8 hours post dose in each period.</time_frame>
        <population>All participants who had at least one study treatment and had evaluable PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Lispro A</title>
            <description>Insulin Lispro A U-200 administered subcutaneously (SC) once in two of four study periods. (Two doses of test [T]).</description>
          </group>
          <group group_id="O2">
            <title>Insulin Lispro B</title>
            <description>Insulin Lispro B U-100 administered SC once in two of four study periods. (Two doses of reference [R]).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Parameter: Time of Maximum Glucose Infusion Rate (tRmax)</title>
          <population>All participants who had at least one study treatment and had evaluable PD data.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="52"/>
                    <measurement group_id="O2" value="2.32" spread="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference of least squares means</param_type>
            <param_value>0.424</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.164</ci_lower_limit>
            <ci_upper_limit>0.685</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameter: Area Under the Curve(AUC)</title>
        <time_frame>Zero to infinity [AUC(0-âˆž)]</time_frame>
        <population>All participants who had at least one study treatment and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Lispro A</title>
            <description>Insulin Lispro A U-200 administered subcutaneously (SC) once in two of four study periods. (Two doses of test [T]).</description>
          </group>
          <group group_id="O2">
            <title>Insulin Lispro B</title>
            <description>Insulin Lispro B U-100 administered SC once in two of four study periods. (Two doses of reference [R]).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: Area Under the Curve(AUC)</title>
          <population>All participants who had at least one study treatment and had evaluable PK data.</population>
          <units>picomole*hour/liter (pmol*h/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2330" spread="15"/>
                    <measurement group_id="O2" value="2360" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric least square means</param_type>
            <param_value>0.992</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.975</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Insulin Lispro A</title>
          <description>Insulin Lispro A U-200 subcutaneously (SC) once in two of four study periods. (Two doses of test [T]).</description>
        </group>
        <group group_id="E2">
          <title>Insulin Lispro B</title>
          <description>Insulin Lispro B U-100 administered SC once in two of four study periods. (Two doses of reference [R]).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Infusion site bruising</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Infusion site swelling</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

